Corporate Backgrounder

MyCareTeam, Inc. was founded to provide software that is designed to help people with chronic diseases manage their disease and reduce overall healthcare costs. The company's diabetes offering, MCT-Diabetes, has been successfully used for over five years by patients, doctors and nurses to dramatically improve the health and wellness in people with diabetes and reduce overall healthcare costs.

Market Overview

Worldwide, there are 194 million people diagnosed with diabetes that use standard glucose meters to check their blood sugar regularly. Within the United States there are over 21 million people with diabetes. One and one-half million new cases are diagnosed each year. The total direct and indirect cost in the US associated with diabetes in 2002 was $132 billion. The human toll of diabetes is enormous. Life-altering complications of diabetes include kidney failure, blindness, amputation, heart failure, and stroke. The nation spends approximately $13,243 on each person with diabetes every year, compared to $2,560 per person for people who do not have diabetes. Medicare expenditures for treating diabetic kidney failure exceed $5.1 billion each year, and diabetes-related amputations cost more than $860 million annually in hospitalization costs alone.

Many studies have found that patients who carefully manage their diabetes enjoy better health than those who do not. The Diabetes Control and Complications Trial (DCCT) is a clinical study conducted from 1983 to 1993 by the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) at the National Institute of Health (NIH). The study showed that keeping blood glucose levels as close to normal as possible slowed the onset and progression of eye, kidney, and nerve diseases caused by diabetes by 50-75% when treated intensively. The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that tight glycemic control and along with aggressive blood pressure management reduce the risk of complications among patients with diabetes.

MCT-Diabetes & Managed Care

MCT-Diabetes allows people with diabetes and their care providers to collaborate and monitor glucose levels across the Internet. Patients with diabetes use MCT-Diabetes to regularly transmit their blood sugar readings directly from their glucose meters to a secure database via the Internet or a standard phone lines. Once the data is stored, physicians, care providers, and family members can use the tool to monitor glucose levels, understand lab values, and examine the effects that exercise and diet have on a person with diabetes' health.

MCT-Diabetes data and reports are accessible over the Internet thus allowing care providers and family members, with permission, to monitor the blood sugar readings of family members—regardless of location. For example, a parent can monitor a child's glucose data while the child is away at college, and an elderly parent living in Florida can be easily monitored by a grown child who lives in Boston.

MyCareTeam is also working on additional Internet-based products to manage other chronic illnesses.

40 Nagog Park
Acton, MA 01720
(978) 635-3930
(978)-635-3917 fax
www.mycareteam.com

Management Team

MyCareTeam, Inc's executive management team has deep experience in both the software and healthcare industries. The founding team combines proven experience building and selling software applications, vast clinical expertise, and a broad understanding of electronic healthcare management and telemedicine.

Studies & Results

MCT-Diabetes has been in active use by specific groups of people with Type 1 and Type 2 diabetes for several years. Appropriate glucose monitoring in groups of people with Type 1 or Type 2 diabetes provides effective management of blood sugar levels as measured by various parameters including HbA1C (Brigham & Women's Hospital and Harvard Medical School: McMahon et al. 2005; Georgetown University Medical Center: Smith et al. 2004) *Endocrinology Practice*

Dr. Stephen Clement, an endocrinologist at Georgetown University Hospital, is using MCT-Diabetes with many of his patients. Dr. Clement's patients are followed regularly by a certified diabetes educator, Cherrel Christian, RN, CDE working with Dr. Clement. The patients are instructed to transfer their blood sugar readings by directly connecting their glucose meters to a computer and uploading the data via MCT-Diabetes. The patients use multiple vendors' glucose meters, including those by Roche Diagnostics, TheraSense/Abbott, and LifeScan. Ms. Christian regularly provides encouragement and information to the patients through the MCT-Diabetes web application and makes treatment changes as identified by Dr. Clement.

Boston Veteran's Administration Hospital Study
(conducted by Brigham & Women's Hospital and Harvard Medical School)

A randomized clinical control trial of MCT-Diabetes was carried out at the Boston Veterans Administration Hospital with 104 patients that were randomly divided into one of two groups- usual care, or web-management with MCT-Diabetes. The study compared Hba1c levels at baseline and after a period of 12 months. The results of this study were published in Diabetes Care, a journal of the American Diabetes Association on July 7, 2005.

Georgetown Study

Patients with diabetes were enrolled in a pilot study of MCT-Diabetes at Georgetown University Medical Center. Patients collected their blood sugar readings using Accu-Check® Complete™ blood glucose meters from Roche Diagnostics, Inc. Patients connected their blood glucose meters to their personal computers with Internet access to transmit their blood glucose readings weekly. The glucose readings were transferred securely over the Internet to a central location where the patients and their care providers had secure access to the clinical data for review. Graphical and statistical representations of their glucose readings and laboratory data highlighted areas of concern and identified patterns in their data. Patients were automatically notified of lab values and blood glucose readings outside of identified target ranges. Providers evaluated the patient's condition in between scheduled office visits. Thus, areas of concern were identified before they became serious problems.

The goal of the Georgetown study was to reduce HbA1c by one-percent for all patients over six-months. HbA1c is a blood test performed that measures long-term glycemic control. An Hba1c of less than 7 is the American Diabetes Association goal.

More details on this study are available from Georgetown University Medical Center.

Other Studies

Funding was recently received to implement MCT-Diabetes at Native American communities across the US within the diabetes and pregnancy group at the National Naval Medical Center in Bethesda, Maryland. Since the MCT-Diabetes technology has already been proven in two previous studies, this study examines how culturally diverse populations respond to the MCT-Diabetes technology and how the technology can be used with the diabetes and pregnancy group of military personnel and their dependents.